<?xml version="1.0" encoding="UTF-8"?>
<p>Assays are now available for detecting IgA, IgM, and IgG specific for SARS-CoV-2 in patient serum, thatÂ is to demonstrate seroconversion, and also for detecting NAbs (
 <xref rid="bib5" ref-type="bibr">Amanat et al., 2020</xref>; 
 <xref rid="bib79" ref-type="bibr">Wu et al., 2020</xref>). These techniques are rapidly evolving, and additional information on the antibody response to CoV-2 infection is emerging almost daily. Analyses of how long predictably protective titers are maintained are still lacking. They will be a priority once enough time has elapsed to allow long-term studies.
</p>
